Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Because Symlin blunts digestion, appetite, and glucagon production at meal times, blood glucose levels can be affected significantly
FDA rejection and regulatory status Development timeline: 2000s: Developed for Parkinson's/Alzheimer's 2008: Phase 2 obesity trials (successful) 2010: Phase 3 trials initiated 2010: Development halted due to safety concerns 2012: FDA rejected obesity indication Present: No approved indication anywhere Why FDA rejected: Cardiovascular safety concerns primary reason Increased heart rate and blood pressure Risk-benefit ratio unfavorable Safer alternatives available ( GLP-1 agonists ) Development company abandoned pursuit No current path to approval Regulatory status by country: Current legal classification: Not a controlled substance (not scheduled) Not approved for any human use Sold as "research chemical" only "Not for human consumption" labels Legal gray area (enforcement rare) See are peptides legal guide at SeekPeptides
Its cardiovascular benefits arise through dose- and tissue-dependent mechanisms: low concentrations predominantly activate AMPK to enhance endothelial function and reduce myocardial injury (Zilov et al., 2019)
Birth control pills may not work as well while using Zepbound
10 , CD013650 (2021)
